This study was done to compare the outcome(mRS) of patients with acute hypertensive hemorrhagic stroke receiving  intravenous fluid vs.  no iv fluids  in the acute period

This was a prospective, single-center, open-label, randomized controlled trial. The outcome assessment was blinded. The patient's relatives were informed that they would have full authority to enroll or withdraw from the study. All the patients with clinical features of acute hypertensive hemorrhagic stroke and were diagnosed with imaging findings between February 2021 and February 2022 were screened for eligibility.

A total of 80 patients were included. All baseline characters, including age, sex, GCS at admission, NIHSS score at admission, ICH volume, ICH score at admission, and mRS at admission, were all comparable between the groups. Out of the total 82 patients included in the analysis, 38 were females (46.3%), and 44 were males (53.7%). The primary outcome was a good functional outcome defined as a mRS of 0-3 at three months of follow-up. We found that those in the IVF group had better and statistically significant good functional outcomes at three months of follow-up than those in the no-IVF group. The mean duration of hospital stay in the IVF group was 7.51±2.81 days and in the no-IVF group, it was 10.49±5.98 days(p<0.001).